DaVita HealthCare Partners (NYSE:DVA)‘s stock had its “hold” rating reissued by stock analysts at KeyCorp in a report released on Wednesday.

DVA has been the subject of several other research reports. SunTrust Banks set a $57.00 price target on DaVita HealthCare Partners and gave the stock a “hold” rating in a report on Sunday, October 15th. Royal Bank Of Canada decreased their target price on DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating for the company in a report on Wednesday, November 8th. Wolfe Research raised DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a report on Monday, October 23rd. J P Morgan Chase & Co downgraded DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a report on Monday, October 9th. Finally, Bank of America decreased their target price on DaVita HealthCare Partners from $75.00 to $66.00 and set a “neutral” rating for the company in a report on Wednesday, November 8th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $63.00.

DaVita HealthCare Partners (DVA) traded down $1.00 on Wednesday, reaching $60.93. The company’s stock had a trading volume of 1,316,400 shares, compared to its average volume of 1,605,100. DaVita HealthCare Partners has a 52 week low of $52.51 and a 52 week high of $70.16. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. The stock has a market capitalization of $11,719.12, a price-to-earnings ratio of 17.69, a PEG ratio of 12.48 and a beta of 0.97.

DaVita HealthCare Partners (NYSE:DVA) last posted its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.13). The company had revenue of $3.92 billion during the quarter, compared to analysts’ expectations of $3.91 billion. DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. DaVita HealthCare Partners’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.95 EPS. research analysts predict that DaVita HealthCare Partners will post 3.42 earnings per share for the current fiscal year.

DaVita HealthCare Partners declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

A number of hedge funds have recently made changes to their positions in DVA. Canada Pension Plan Investment Board raised its position in DaVita HealthCare Partners by 33.1% during the second quarter. Canada Pension Plan Investment Board now owns 387,370 shares of the company’s stock valued at $25,086,000 after acquiring an additional 96,282 shares in the last quarter. Pzena Investment Management LLC raised its position in DaVita HealthCare Partners by 2.1% during the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock valued at $220,000 after acquiring an additional 71 shares in the last quarter. Airain ltd purchased a new position in DaVita HealthCare Partners during the second quarter valued at approximately $2,234,000. Jensen Investment Management Inc. raised its position in DaVita HealthCare Partners by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock valued at $631,000 after acquiring an additional 1,900 shares in the last quarter. Finally, Schroder Investment Management Group raised its position in DaVita HealthCare Partners by 53.9% during the second quarter. Schroder Investment Management Group now owns 49,967 shares of the company’s stock valued at $3,201,000 after acquiring an additional 17,497 shares in the last quarter. Institutional investors own 85.32% of the company’s stock.

TRADEMARK VIOLATION WARNING: “DaVita HealthCare Partners (DVA) Stock Rating Reaffirmed by KeyCorp” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/06/davita-healthcare-partners-dva-stock-rating-reaffirmed-by-keycorp.html.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.